White House lays out sprawling new plan to shore up pharma and API manufacturing
As the US increasingly relies on foreign drug and active pharmaceutical ingredient (API) manufacturing, particularly from China and India, the Biden-Harris administration early Tuesday morning released a new report spelling out how the US needs to better tackle the three pillars of a robust and resilient supply chain by boosting quality, location diversity, and redundancy.
Whereas the pandemic laid bare how much the US relies on essential imports, the previous administration focused its supply chain efforts on adding new domestic manufacturing, with investments in upstart Phlow, and a questionable $765 million loan through the administration’s development finance arm to camera maker Kodak.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.